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OBJECTIVES This randomized trial compared repeat stenting with balloon angioplasty (BA) in patients
with in-stent restenosis (ISR).
BACKGROUND Stent restenosis constitutes a therapeutic challenge. Repeat coronary interventions are
currently used in this setting, but the recurrence risk remains high.
METHODS We randomly assigned 450 patients with ISR to elective stent implantation (224 patients) or
conventional BA (226 patients). Primary end point was recurrent restenosis rate at six
months. Secondary end points included minimal lumen diameter (MLD), prespecified
subgroup analyses, and a composite of major adverse events.
RESULTS Procedural success was similar in both groups, but in-hospital complications were more
frequent in the balloon group. After the procedure MLD was larger in the stent group (2.77
 0.4 vs. 2.25  0.5 mm, p  0.001). At follow-up, MLD was larger after stenting when
the in-lesion site was considered (1.69  0.8 vs. 1.54  0.7 mm, p  0.046). However, the
binary restenosis rate (38% stent group, 39% balloon group) was similar with the two
strategies. One-year event-free survival (follow-up 100%) was also similar in both groups
(77% stent vs. 71% balloon, p  0.19). Nevertheless, in the prespecified subgroup of patients
with large vessels (3 mm) the restenosis rate (27% vs. 49%, p  0.007) and the event-free
survival (84% vs. 62%, p  0.002) were better after repeat stenting.
CONCLUSIONS In patients with ISR, repeat coronary stenting provided better initial angiographic results but
failed to improve restenosis rate and clinical outcome when compared with BA. However, in
patients with large vessels coronary stenting improved the long-term clinical and angiographic
outcome. (J Am Coll Cardiol 2003;42:796–805) © 2003 by the American College of
Cardiology Foundation
Coronary stenting is increasingly used during coronary
interventions (1–3). Treatment of in-stent restenosis (ISR),
however, represents a technical and clinical challenge (4–
11). Satisfactory initial results are usually obtained with
conventional balloon angioplasty (BA), but the risk of
recurrent restenosis remains high (4–11). Therefore, the use
of alternative mechanical approaches, such as debulking
techniques, has been advocated (12–14). However, a recent
randomized study (13) failed to demonstrate benefits of
rotational atherectomy in these patients. Angiographic and
intravascular ultrasound studies suggest that repeated coro-
nary interventions do not obtain the same results that were
achieved during initial stent implantation (4,7,11). Accord-
ingly, suboptimal procedural results could explain the un-
satisfactory course of some patients. In addition, although
the effectiveness of coronary brachytherapy has been clearly
demonstrated in this setting, it is not widely available and it
has inherent problems and limitations (15–18). There is,
therefore, still a need to determine which mechanical interven-
tion is best suited for patients with ISR, a problem affecting up
to 150,000 patients annually in the U.S. alone (18).
In some patients treated for ISR, a new “unplanned” stent
implantation is eventually required to achieve a satisfactory
final angiographic result (19–22). Preliminary reports (21,22)
have suggested the potential value of “elective” stenting (used
as the primary strategy) in these patients. Nevertheless, the
outcome of patients with ISR electively treated by the implan-
tation of a new stent remains largely unknown.
We hypothesized that repeat coronary stenting could
improve the initial angiographic results of patients with ISR
and that this might translate into better long-term clinical and
angiographic outcomes. Therefore, we conducted a multi-
center randomized trial to compare elective coronary stenting
with conventional BA in these patients.
METHODS
Patient selection and study design. Patients with angina
or objective evidence of myocardial ischemia undergoing
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repeat coronary interventions for ISR (50% stenosis on
visual estimation) were eligible if they had lesions amenable
to both interventional strategies. The target lesion had to be
a first ISR that could be spanned by a single stent (32 mm
in length) and had to be located in a vessel 2.5 mm in
diameter. Lesions located in severely tortuous or calcified
vessels and those presenting as total occlusions were ex-
cluded. Patients with prior stent implantation within the
previous month, severe concomitant systemic illness, and
conditions likely to preclude follow-up angiography were
not included. The study was carried out following the
principles of the Declaration of Helsinki regarding investi-
gations with human subjects (23) and the recommendations
for conducting/reporting randomized trials (24). Written
informed consent was obtained from all patients. Random-
ization was performed by telephone, using a computer-
generated code, and was stratified according to restenosis
length.
At the coordinating center, data were verified by consis-
tency checks, and double data set entry and queries about
any missing or inconsistent data were sent back to the sites.
Summaries of clinical records from all patients with poten-
tial events were also reviewed at the coordinating center.
Subsequently, all events were classified and adjudicated by
an independent clinical events committee unaware of the
assigned treatment.
Coronary interventions. All patients were pretreated with
aspirin, and 100 IU/kg of heparin was given as a bolus at the
beginning of the procedure. Balloon size was selected with
the aim of achieving a final balloon-to-artery ratio of 1.1/1.
Relatively high pressures (12 atm) were recommended in
both arms. In patients allocated to repeat stenting the stent
was deployed after a previous balloon dilation of the lesion.
Because the strategy of repeated stenting (rather than the
value of any specific stent design) was under investigation,
three different noncoil stent designs were selected for the
study: the NIR stent (Boston Scientific, Maple Grow,
Minnesota) (106 patients), the Crown stent (Cordis, John-
son and Johnson, Warren, New Jersey) (46 patients), and
the Bestent (Medtronic-AVE, Santa Rosa, California) (45
patients). However, in 24 patients other noncoil stent types
were eventually implanted for logistic reasons or operator
preferences. Crossover to the other treatment method was
strongly discouraged. In all cases repeated prolonged bal-
loon inflations had to be attempted before crossover to stent
deployment. Crossover was allowed only in patients with
persistent stenosis 50%, major coronary dissections (Na-
tional Heart, Lung, and Blood Institute types D-F), or
dissections associated with ischemia.
Creatine kinase levels (with myocardial isoenzymes if
abnormal) and 12-lead electrocardiograms (ECGs) were
obtained before the procedure and every eight hours after-
wards for 24 h. Personnel blinded to the assigned treatment
reviewed the ECGs. Procedural success was defined as
angiographic success (residual stenosis 50%) in the ab-
sence of major complications. Myocardial infarction (MI)
was considered in the presence of two of the following:
prolonged (30 min) chest pain, new Q-waves (0.04 s),
and increase in the creatine kinase level more than twice the
upper normal value (with a MB fraction 10% of the total
value). All patients received aspirin indefinitely, whereas
patients treated with repeated stenting also received ticlo-
pidine (500 mg daily) for one month. Patients were followed
up at one, six, and seven months and at one year. An
exercise test was recommended immediately before the
follow-up angiography. Angiographic follow-up was ob-
tained routinely at six months or earlier if clinically indi-
cated. Follow-up angiographic data obtained 3 months
after the index procedure were excluded unless restenosis
was documented; otherwise, the patient was asked to
undergo the scheduled angiogram at six months.
Objectives. The primary end point was the recurrent
restenosis rate “per segment.” Secondary end points in-
cluded: 1) the analysis of the influence of 10 prespecified
relevant variables on the restenosis rate according to the
assigned treatment (age, gender, diabetes, unstable angina,
time to restenosis, left anterior descending coronary artery
location, reference vessel 3 mm, diffuse [10 mm] reste-
nosis, stent type, and balloon/artery ratio); 2) comparison of
minimal lumen diameters (MLDs) at follow-up; 3) com-
parison of angiographic findings confined to the “in-lesion”
analysis; and 4) assessment of a combined clinical end point
at one year follow-up.
Angiographic analysis. Multiple coronary views were ob-
tained after the administration of intracoronary nitroglyc-
erin (0.2 mg). All cine films or CDs were analyzed at the
centralized angiographic core laboratory and reviewed by
experienced personnel blind to the assigned treatment (25).
Special care was taken in trying to identify the site of initial
stent deployment—before the injection of contrast materi-
al—and subsequently the relative location of the lesion.
Detailed drawings of these two sites (requested on the case
report forms) were also reviewed. Quantitative coronary
angiographic analysis was carried out using a validated,
automatic edge-detection algorithm (MEDIS, CMS 4.0,
Leiden, the Netherlands) (26). Matched angiographic views
were reviewed before, after intervention and at follow-up. A
first analysis was confined at the lesion site “in-lesion
analysis” (site showing the initial narrowing), and a second
analysis considered “the segment” that encompassed the
lesion site, the treated region, and the adjacent 5 mm of the
Abbreviations and Acronyms
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vessel on each side. This methodology has been used in
previous controlled trials (18,27). A binary definition for
restenosis (stenosis 50% at follow-up) was used.
Statistical analysis. On the basis of data from a previous
pilot study of repeated stenting for ISR (21) and prior studies
of BA in this setting (7) (2/3 of patients presenting diffuse
ISR), a recurrent restenosis rate of 30% and 45% was
estimated in the stent and balloon groups respectively.
Given these assumptions we required 185 in each group to
be able to detect a 30% reduction in the restenosis rate with
repeat stenting with a power (1-beta) of 90% and a type I
error (alpha) of 5%. To compensate for non-evaluable
patients at follow-up (10% expected, because of patient
refusal or poor-quality angiograms), the sample size was
increased to a total number of 450 patients. Comparisons
were performed according to the intention-to-treat princi-
ple. Categorical data were compared with the chi-square
test or Fisher exact test (when expected values were 5).
For the comparison of continuous variables a two-tailed
Student t test (normally distributed data) or Wilcoxon
rank-sum nonparametric test were used. Rates of event-free
survival were studied with Kaplan-Meier analysis and com-
pared with the log-rank test. Cox proportional hazards
models were also used to assess events. The 10 prespecified
subgroups, were examined for interactions (28,29) using a
logistic regression model. The p value of the interaction
terms was corrected with the Bonferroni test. Analyses were
performed using the SPSS package (version 10.0). A p value
0.05 was considered statistically significant.
RESULTS
Hospital results. Between December 1997 and December
1999, 450 patients were enrolled at 24 investigational sites
from Spain and Portugal; 224 patients were assigned to
repeat stent implantation and 226 to balloon treatment
(Fig. 1). Baseline demographic, clinical, and angiographic
data (Table 1) were well matched in the two groups.
Procedural characteristics were also similar, although higher
inflation pressures and shorter total balloon inflation times
were used in the stent arm (Table 1).
Angiographic success (448 patients, 99%) was obtained in
all but one patient in each group. Procedural success was
similar in both groups (98% stent group, 95% balloon group,
p  0.11). Crossover to the other strategy was required in
only 16 patients, 13 (5.7%) in the balloon group and 3
(1.3%) in the stent group (p  0.02). All but 11 patients
(5%) in the stent group were treated with single stents
(mean stented length 19  6 mm). During hospitalization
2 patients died, 11 developed MI (Q-wave in 1), and 1
Figure 1. Trial profile. Of 891 consecutive patients undergoing repeat coronary interventions for in-stent restenosis during the study period, 450 (51%) were
included in the trial. BA  balloon angioplasty arm; FU  follow-up; PCI  percutaneous coronary intervention; QCA  quantitative coronary
angiography; ST  stent arm.
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patient (with initial angiographic failure) required elective
surgery before discharge (Table 2). Two patients experi-
enced subacute vessel occlusion during admission and re-
quired repeat interventions (one fulfilled the study criteria of
MI). Altogether there were fewer hospital complications in
the stent group (Table 2).
Angiographic findings. Angiographic data before and im-
mediately after the procedure are summarized in Table 3
Table 1. Baseline Clinical, Angiographic, and Procedural Characteristics
Characteristic
Stent Group
(n  224)
Balloon Group
(n  226)
Age (yrs) 61  11 61  11
Female gender, no. (%) 59 (26) 42 (19)
Risk factors, no. (%)
Diabetes mellitus 60 (27) 58 (26)
Hyperlipidemia 132 (59) 117 (53)
Hypertension 131 (59) 116 (51)
Ever smoked 122 (55) 136 (60)
Clinical features, no. (%)
Unstable angina 102 (45) 92 (41)
Stable angina 105 (47) 119 (53)
Silent ischemia* 17 (8) 15 (6)
Previous myocardial infarction 98 (44) 95 (42)
Previous bypass surgery* 9 (4) 10 (4)
Time to restenosis, days† 180 (132–230) 180 (124–228)
Target artery, no. (%)
Left anterior descending 105 (47) 130 (57)
Left circumflex 50 (22) 38 (17)
Right coronary 65 (29) 53 (24)
Saphenous vein graft* 4 (2) 5 (2)
Multivessel disease 108 (48) 92 (41)
Ejection fraction (%) 65  12 64  12
Procedural characteristics
Maximal pressure (atm) 13.5  2.2 12.6  2.8‡
Total inflation time (s) 131  86 176  120§
Final balloon diameter (mm) 3.14  0.4 3.09  0.4
IIb/IIIa inhibitors 4 (2%) 8 (4%)
*Fisher exact test. †Median and interquartile range (25th to 75th percentile) (Wilcoxon test). ‡p 0.001, §p 0.01. Plus-minus
values are means  SD.
Table 2. In-Hospital and One Year Clinical Events
Event
Stent Group
(n  224)
Balloon Group
(n  226) p Value
Relative Risk
(95% CI)
Hospital events, no. (%)
Death 1 (0.4) 1 (0.4) 1 1 (0.06–16.03)
Myocardial infarction 2 (0.9) 9 (4) 0.06 0.22 (0.05–1.03)
Target vessel revascularization 1 (0.4) 2 (0.9) 1 0.50 (0.046–5.52)
Coronary angioplasty 1 (0.4) 1 (0.4) 1 1 (0.06–16.03)
Coronary surgery 0 (0) 1 (0.4)
Any major hospital event 3 (1.3) 11 (4.9) 0.039 0.27 (0.078–0.97)
Events at 7 months, no. (%)
Death 5 (2.2) 4 (1.8) 0.75 1.26 (0.34–4.64)
Myocardial infarction 5 (2.2) 12 (5.3) 0.13 0.42 (0.15–1.17)
Target vessel revascularization 37 (16.5) 39 (17.3) 0.9 0.96 (0.63–1.44)
Coronary angioplasty 27 (12) 29 (12.8) 0.89 0.94 (0.57–1.53)
Coronary surgery 12 (5.4) 11 (4.9) 0.83 1.10 (0.49–2.44)
Any major event at 7 months 42 (19) 47 (21) 0.64 0.90 (0.62–1.31)
Events at 1 yr, no. (%)
Death 8 (4) 7 (3) 0.8 1.15 (0.42–3.12)
Myocardial infarction 6 (2.7) 13 (5.8) 0.15 0.46 (0.18–1.20)
Target vessel revascularization 44 (19.6) 55 (24.3) 0.25 0.81 (0.57–1.14)
Coronary angioplasty 32 (14) 43 (19) 0.20 0.75 (0.49–1.14)
Coronary surgery 14 (6.3) 13 (5.8) 0.84 1.08 (0.52–2.26)
Any major event at 1 yr () 52 (23) 65 (29) 0.19 0.81 (0.58–1.10)
Patients with more than one event are counted only once for the composite clinical end points, although each event is listed
separately in the corresponding category.
CI  confidence interval; ()  a prespecified secondary study end point (p values from Cox analysis).
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and Figure 2. Of the 262 lesions with diffuse restenosis, 99
had a proliferative pattern (14). Reference vessel size and
MLD before intervention were similar in the two groups.
After the procedure, however, angiographic results were
significantly better in the stent group. Patients in the stent
group obtained a larger final MLD and had a larger acute
gain and a lower residual diameter stenosis compared with
those in the balloon group.
Quantitative coronary angiographic follow-up data
(Table 3, Fig. 2) were obtained in 415 of 439 (95%) eligible
patients (median 188 days, similar in both groups) (Fig. 1).
Although MLD at follow-up (“per-segment” analysis) was
larger in the stent group, this difference was no longer
significant (p  0.17). However, when the more stringent
“in-lesion” analysis was used, patients in the stent group
obtained a significantly better MLD at follow-up (p 
0.046) and a larger net gain (Table 3). The binary restenosis
rate per segment analysis was similar in the two groups (38%
stent group vs. 39% balloon group). Restenosis rates for
patients with focal (27% vs. 26%), diffuse (39% vs. 43%) and
proliferative (58% vs. 59%) ISR were similar with the two
techniques. In addition, the restenosis rate using the “in-
lesion” analysis was also similar (33% stent arm vs. 38%
balloon arm, p  0.36) (Table 3). The “per-protocol”
angiographic analysis did not differ from the primary inten-
tion to treat analysis. In the stent arm no differences could
be identified among the three stents used (p for interaction
0.29). Finally, the influence of the 10 prespecified variables
on treatment effect is summarized in Figure 3. On logistic
regression analysis there was a significant vessel-size/
treatment-effect interaction (p  0.001, p  0.01 after the
Bonferroni correction). In patients with large vessels (refer-
ence diameter 3 mm), the binary restenosis rate was
significantly reduced after stenting (27% vs. 49%, p 0.007;
risk ratio 0.55, 95% confidence interval 0.35 to 0.85). In
clinical terms, four patients with ISR in large vessels would
need to be treated by repeat stenting to prevent one episode
of recurrent restenosis. Conversely, in patients with small
vessels (2.6 mm, lower tercile) the restenosis rate (59% vs.
41%, p  0.053) tended to be higher in the stent group.
Clinical follow-up. All 450 patients were followed up for
one year with no patient lost to follow-up (Table 2). Of the
99 patients undergoing target vessel revascularization during
follow-up, 96 (97%) had angina or documented ischemia (as
required by protocol), but in 3 patients (1 stent group, 2
balloon group) only an “anatomic indication” led to repeat
intervention. Although the clinical outcome was similar in
the two groups a nonsignificant trend (p  0.19) was found
for a poorer event-free survival in the balloon group (Fig. 4),
mainly because a larger number or patients required target
vessel revascularization. In patients with large vessels, how-
ever, the one-year event-free survival was significantly better
in the stent group (Fig. 4). This difference was largely
determined by a reduced need for repeat interventions (13%
vs. 34%, p  0.002).
Table 3. Initial and Follow-Up Angiographic Results
Variable Stent Group Balloon Group p Value
Before the procedure (n  224) (n  226)
Reference vessel diameter (mm) 2.87  0.5 2.83  0.5 0.24
Minimal lumen diameter (mm) 0.68  0.4 0.67  0.4 0.79
Stenosis (% of lumen diameter) 76  12 76  12 0.95
Lesion length (mm) 12.7  6 13.0  7 0.62
Diffuse lesions (10 mm), no. (%) 132 (60) 130 (59) 1
After the procedure (n  224) (n  226)
Reference vessel diameter (mm) 3.12  0.4 2.92  0.5  0.001
Minimal lumen diameter (mm) 2.77  0.4 2.25  0.5  0.001
Stenosis (% of lumen diameter) 12  10 23  10  0.001
Acute gain (mm) 2.08  0.5 1.58  0.5  0.001
At follow-up (“per segment” analysis) (n  206) (n  209)
Reference vessel diameter (mm) 2.91  0.5 2.82  0.5 0.042
Minimal lumen diameter (mm) 1.63  0.8 1.52  0.7 0.17
Stenosis (% of lumen diameter) 45  25 46  23 0.82
Restenosis, no (%) 79 (38) 82 (39) 0.92
Late loss (mm) 1.12  0.8 0.73  0.7  0.001
Loss index 0.55  0.4 0.42  0.5 0.004
Net gain (mm) 0.95  0.8 0.84  0.7 0.13
At follow-up (“in lesion” analysis) (n  206) (n  209)
Reference vessel diameter (mm) 2.91  0.5 2.82  0.5 0.03
Minimal lumen diameter (mm) 1.69  0.8 1.54  0.7 0.046
Stenosis (% of lumen diameter) 43  24 45  23 0.31
Restenosis, no. (%) 69 (33) 80 (38) 0.36
Late loss (mm) 1.06  0.7 0.72  0.7  0.001
Loss index 0.52  0.4 0.42  0.5 0.02
Net gain (mm) 1.01  0.8 0.85  0.68 0.03
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DISCUSSION
This study has demonstrated the value of stent implantation
in patients with ISR. This technique reduced the risk of
procedure-related complications and provided much better
immediate angiographic results but failed to reduce the rate
of recurrent restenosis compared with BA. In fact, MLD at
follow-up was better after stenting only when the “in-lesion”
Figure 2. Cumulative frequency distribution curves of the minimal lumen diameter before the procedure (PRE), immediately after intervention (POST),
and at six months follow-up (FU), in patients treated with balloon angioplasty (BA) and repeat stenting (ST). (A) “Per-segment” analysis. (B) “In-lesion”
analysis. After the procedure the distribution curve in the stent group is shifted to the right (with the two analyses) indicating a larger acute gain. At
follow-up the results of the stent group are better than those in the balloon group in the “in-lesion” analysis (B), but not in the “per-segment” analysis (A).
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segment was taken into consideration. The study also
suggests that in patients with large vessels (3 mm) repeat
stenting appears to have long-term clinical and angiographic
benefits beyond those obtained with BA and, therefore,
should be recommended.
The current study shows that repeat stenting is safe and
can be readily accomplished. Indeed, the occurrence of
procedure-related complications was higher in the balloon arm.
A previous observational study comparing BA with repeat
stenting in patients with “focal” ISR (22) suggested that
patients treated with BA had a higher rate of major in-hospital
complications (death, Q-wave infarction, urgent revasculariza-
tion). Although procedure-related complications in patients
with ISR may be the result of side-branch occlusion, this event
rarely results in clinically evident myocardial necrosis (9). Some
of the MIs documented in our study were the result of
crossover to stenting after a complicated BA procedure. The
potential implication of the antiplatelet therapy imbalance in
this regard is of interest but remains speculative.
Compared with conventional BA elective restenting pro-
vided much better immediate angiographic results because
of a larger acute gain. These findings confirm that repeat
stenting can guarantee an excellent immediate angiographic
result in these patients (20–22). Nevertheless, recurrent
restenosis rates were eventually high and similar with both
techniques. The greater late loss and late loss-index seen in
the stent group suggest that this strategy elicits a more
profound proliferative response. Although the MLD at
Figure 3. Rates, relative risks, and confidence intervals (CI) of restenosis according to the 10 prespecified variables. P values for the interaction (logistic
regression analysis) were only significant for reference vessel size (p 0.001). BA balloon angioplasty; B/A balloon to artery ratio; LAD left anterior
descending coronary artery; RE  restenosis; ST  stent.
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Figure 4. Kaplan-Meier estimates of the event-free survival at one year (death, myocardial infarction, or target vessel revascularization) according to
treatment group. No differences were found between the two groups in the entire 450-patient population (Cox hazard ratio 0.81, 95% confidence interval
[CI] 0.56 to 1.17) (A), but the event-free survival in patients with large vessels (3 mm) (B) was significantly greater in the stent group (Cox hazard ratio
0.31, 95% CI 0.2 to 0.73). This difference was due to the lower proportion of patients in the stent group that required target vessel revascularization. Note
survival scales cut off at 60%. BA  balloon angioplasty; ST  stent.
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follow-up was similar in the two groups on the “per-
segment” analysis, better results were found after stenting
when the analysis was focused on the “in-lesion” site. This
may be relevant from the pathophysiologic point of view,
suggesting that in some patients undergoing repeat stenting,
a relocation of minimal lumen diameter at follow-up or
“edge-effect” (27) may produce recurrent restenosis outside
the site encompassed by the second stent.
The event-free survival at one year was also similar with
the two techniques, with most patients having a satisfactory
long-term outcome. The trend for a larger MLD at
follow-up after repeat stenting could explain the associated
trend toward a better long-term clinical outcome resulting
from a reduction in the need for repeat interventions. In
addition, the significant number of revascularization proce-
dures after six months is of interest but also may have been
driven by the requirement to demonstrate ischemia before
proceeding with further revascularization. In this regard, an
even longer clinical follow-up would have been of clinical
relevance and this is currently planned for these patients.
Finally, an important study finding was the evidence of a
major interaction between treatment effect and vessel size.
In this study we prospectively predefined our subgroups of
interest to determine potential interactions (28,29). In
patients with large vessels (3 mm) elective stenting not
only significantly reduced the restenosis rate compared with
BA, but also improved the long-term clinical outcome. This
significant “treatment effect size” (calculated power 80%)
emerges from the analysis of a secondary study end point but
has the inherent limitations of subgroup analyses. However, in
our opinion, it is clinically relevant and may have implications
for patient management. The striking difference in clinical
outcomes between the stent and balloon groups in patients
with large vessels was primarily due to the need for fewer repeat
interventions on the target vessel. This parallels previous
studies showing that the main clinical benefit of stenting in
native coronary lesions occurs in large vessels as the result of a
reduction in the number of reinterventions (1,2,30).
Conversely, in patients with small vessels repeat stenting
was associated with a relatively high restenosis rate, and
probably should be avoided. Although by design we tried to
exclude patients with small vessels from this trial, one-third
of our patients (with vessels 2.5 mm on visual estimation)
actually had small vessels by quantitative angiography.
Again, these findings mirror those found in “de novo”
lesions, where the value of stenting in small vessels is, at
least, controversial (31,32).
Repeat stenting, therefore, constitutes an attractive strat-
egy for patients with ISR in large vessels. Alternatively, for
most patients with small vessels and a focal pattern of
restenosis BA should be preferred. Brachytherapy, however,
currently remains the cornerstone of therapy for patients
presenting with the vexing problem of diffuse ISR (15–18),
where both angioplasty and repeat stenting are shadowed by
an unacceptably high recurrence rate. Repeat stenting
should not be recommended in combination with brachy-
therapy owing to the potential risk of late thrombosis (33).
Last, we used conventional stainless-steel stents in the
present study. Our findings underscore the importance of
assessing the results of restenting using the new drug-eluting
stents. Because drug-coated stents prevent subsequent neoin-
timal proliferation to a large extent (34), they appear to be
ideally suited for the treatment of patients with ISR (35,36).
However, the potential concern for edge effects should also be
investigated with these new stents in patients with ISR.
Conclusions. Although some observational studies have
suggested a potential benefit of “stenting the stent” for patients
with ISR in this large multicenter randomized controlled trial
repeat stenting failed to reduce the rate of recurrent restenosis
when compared with BA. Nevertheless, our findings suggest
that in patients with large vessels repeat stenting provides
better long-term results and should be recommended.
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APPENDIX
The design and execution of the protocol as well as the analysis
of the data were conducted at the coordinating center in a
manner absolutely independent of the sponsors (research
grants from Boston Scientific, Cordis [Johnson and Johnson],
Medtronic) that had no access to the results of the trial until
the analysis of the study objectives had been finalized.
The Restenosis Intra-stent: Balloon angioplasty versus
elective Stenting (RIBS) Investigators, Coordinators, and
Sites were the following:
Coordinating Center: Hospital Universitario San Car-
los, Madrid.
Steering Committee: F. Alfonso (Principal Investiga-
tor), A. Cequier, C. Morı´s, J. Zueco, A. Bethencourt,
R. Seabra-Gomes, C. Macaya. Clinical Events Commit-
tee: E. Esplugas, A. Cortina, P. Zarco. Coronary Angiog-
raphy Core Laboratory: (Hospital Universitario San Car-
los, Madrid) J. Goicolea, J. Escaned. Data Coordination,
Safety Monitoring and Statistical Committee: C. Ferna´n-
dez, M.J. Pe´rez-Vizcayno. Intravascular Ultrasound Com-
mittee: M. Sabate´, F. Alfonso. Economics Committee:
V. Mainar, R. Melgares.
Sites and Investigators: In order of enrollment (number
of randomized patients): Spain: Hospital Universitario San
Carlos, Madrid (86, F. Alfonso, C. Macaya, R. Herna´ndez);
Hospital Universitario Marque´s de Valdecilla, Santander (43,
J. Zueco, T. Colman); Hospital Universitario Bellvitge, Bar-
celona (41, A. Cequier, E. Esplugas); Hospital Meixoeiro,
Vigo (30, R. Mantilla, J. Goicolea); Hospital Universitario de
Son Dureta, Palma de Mallorca (29, A. Bethencourt); Hospi-
tal Universitario Infanta Cristina, Badajoz (24, J.R. Lo´pez-
Minguez); Hospital Universitario Valle de Hebro´n, Barcelona
(22, J. Angel); Hospital Universitario Santa Cruz y San Pablo,
Barcelona (22, J.M. Auge´); Hospital Universitario La Princesa,
Madrid (21, M. Go´mez-Recio); Hospital Clı´nico, Valencia
(13, L. Insa); Hospital Miguel Servet, Zaragoza (12, I. Calvo);
Hospital Virgen de la Victoria, Ma´laga (11, J.M. Herna´ndez);
Hospital Carlos Haya, Ma´laga (11, J.A. Bullones); Hospital
Virgen de las Nieves, Granada (11, R. Melgares); Hospital
Central de Asturias, Oviedo (11, C. Morı´s); Hospital Provin-
cial de Navarra, Pamplona (9, R. Lezau´n); Hospital de Ali-
cante, Alicante (9, V. Mainar); Hospital Juan Canalejo, La
Corun˜a (9, N. Va´zquez); Hospital Universitario “12 Octubre,”
Madrid (8, J. Tasco´n); Hospital General Valencia, Valencia (5,
F. Pomar). Portugal: Hospital S. Joao, Porto (8, J Mota-
Garcı´a); Hospital Santa Cruz, Lisboa (7, R. Seabra-Gomes);
Hospital Vila Nova de Gaia, Porto (4, V. Gama-Ribeiro);
Centro Hospitalar de Coimbra, Coimbra (4, A. Leitao-
Marques).
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